Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk. Is Prostacyclin Inhibition the Key Event?

Journal of the American College of Cardiology

Volumn 52, Issue 20, 2008, Pages 1637-1639

  Minuz, Pietro ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

cardiovascular risk; cyclooxygenase; myocardial infarction; nonsteroidal anti inflammatory drugs; prostacyclin; thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE A2;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG SAFETY; DRUG SELECTIVITY; EDITORIAL; ENZYME INHIBITION; ENZYME RELEASE; HEART INFARCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SIDE EFFECT; SODIUM RETENTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

CYCLOOXYGENASE 2 INHIBITORS; EPOPROSTENOL; HUMANS; MYOCARDIAL INFARCTION;

EID: 55049091594     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.08.042     Document Type: Editorial

References (17)

1. Patrignani P., Panara M.R., Greco A., et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271 (1994) 1705-1712
2. McAdam B.F., Catella-Lawson F., Mardini I.A., et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. [Erratum in: Proc Natl Acad Sci U S A 1999;96:5890]. Proc Natl Acad Sci U S A 96 (1999) 272-277
3. 2. Science 296 (2002) 539-541
4. Arehart E., Stitham J., Asselbergs F.W., et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 102 (2008) 986-993
5. Aw T.J., Haas S.J., Liew D., and Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165 (2005) 490-496
6. Grosser T., Fries S., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 (2006) 4-15
7. Patrono C., García Rodríguez L.A., Landolfi R., and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
8. Bresalier R.S., Sandler R.S., Quan H., et al., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. (erratum in: N Engl J Med 2006;355:221). N Engl J Med 352 (2005) 1092-1102
9. Laine L., Curtis S.P., Cryer B., et al., MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369 (2007) 465-473
10. Capone M.L., Tacconelli S., Di Francesco L., et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostagland Other Lipid Mediat 82 (2007) 85-94
11. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
12. García Rodríguez L.A., Tacconelli S., and Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52 (2008) 1628-1636
13. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
14. Warner T.D., and Mitchell J.A. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371 (2008) 270-273
15. Capone M.L., Tacconelli S., Sciulli M.G., et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109 (2004) 1468-1471
16. Reilly A.G., and FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69 (1987) 180-186
17. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 99 (2006) 1293-1304